Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding Ltd (OP: RHHVF ) 299.84 -2.98 (-0.98%) Streaming Delayed Price Updated: 3:45 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding Ltd < Previous 1 2 3 4 5 6 7 Next > Sarepta Therapeutics Inc.: Why it's a rising gene therapy star January 23, 2024 Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. Via MarketBeat Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M January 02, 2024 Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. Via Benzinga Exposures COVID-19 Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial December 11, 2023 Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen... Via Benzinga Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation December 05, 2023 Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti Via Benzinga Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs December 04, 2023 Roche Holding AG (OTC: RHHBY) has agreed to Via Benzinga Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks October 31, 2023 Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)... Via Benzinga Exposures Product Safety Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products October 19, 2023 Roche Holdings AG's (OTC: RHHBY) nine months Via Benzinga Exposures COVID-19 What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? October 17, 2023 Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC: Via Benzinga Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready October 11, 2023 Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... Via Benzinga Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges September 27, 2023 Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY Via Benzinga Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year September 21, 2023 In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. Via Benzinga Exposures COVID-19 Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope September 07, 2023 Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, Via Benzinga Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer September 01, 2023 Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)... Via Benzinga Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time August 30, 2023 The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme Via Benzinga Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update August 23, 2023 Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... Via Benzinga Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study August 23, 2023 Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t Via Benzinga Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs Via Benzinga Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations July 28, 2023 Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. Via Benzinga Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List July 26, 2023 The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen Via Benzinga Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy July 24, 2023 Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to Via Benzinga Nvidia Invested $50 million into This AI Drug Discovery Biotech July 17, 2023 Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal July 14, 2023 Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) Via Benzinga Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion July 13, 2023 Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... Via Benzinga Agilent Technologies Stock: Ready to Rise off the Floor June 21, 2023 Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. Via MarketBeat DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth June 21, 2023 DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. Via MarketBeat Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma June 16, 2023 The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)... Via Benzinga New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control June 09, 2023 Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e Via Benzinga Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows May 17, 2023 Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) Via Benzinga Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline April 26, 2023 Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency) Via Benzinga FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma April 20, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
